Products
Phenylpropanolamine is no longer on the market as a human drug in many countries. It was formerly contained in Astho-Med Syrup, Contac, Dimetane, Dimetapp, and Slim Caps, among others.
Structure and properties
Phenylpropanolamine (C9H13NO, Mr = 151.21 g/mol) has a phenylethylamine structure and exists as a racemate. The salt phenylpropanolamine hydrochloride is a white crystalline powder that is readily soluble in water. It is related to ephedrine and is also known as D,L-norephedrine.
Effects
Phenylpropanolamine (ATC R01BA01) has indirect sympathomimetic and appetite suppressant properties. Because of the possible adverse cardiovascular effects, the drug should not be taken in our opinion.
Indications
- For short-term treatment of obesity during four weeks (no longer approved in many countries).
- Rhinitis, common cold (no longer approved in many countries).
- Urinary incontinence in dogs, as a veterinary medicine.
Abuse
Phenylpropanolamine is a centrally stimulating sympathomimetic and can be abused as an intoxicant or party drug, as well as a precursor chemical. Therefore, when dispensing veterinary drugs, it should be clarified whether the drug is actually intended for a dog.
Contraindications
- Hypersensitivity
- High blood pressure
- Dizziness
- Cardiac arrhythmia
- Cardiovascular diseases
- Diabetes mellitus
- Kidney disease
- Thyroid diseases
- Prostate enlargement
- Narrow-angle glaucoma
- Pheochromocytoma
- Pregnancy and lactation
- Children under 12 years
Full precautions can be found in the drug label.
Interactions
Drug-drug interactions are possible with guanethidine, other sympathomimetics, halothane, and MAO inhibitors.
Adverse effects
Possible adverse effects include rapid heartbeat, hypertension, cardiac arrhythmias, headache, irritability, drowsiness, nervousness, dizziness, urinary retention, and personality changes. Continuous use may lead to dependence. Phenylpropanolamine has been linked to serious cardiovascular disease such as stroke and heart attack.
